Business Context and Reporting Period
This Form 8-K Current Report from Keurig Dr Pepper Inc. (KDP) covers the period ending May 22, 2020, with the earliest event reported on May 20, 2020. The filing details the completion of a registered public secondary offering of the company's common stock.
Key Financial Metrics
The filing reports the following specific financial data related to the secondary offering:
- Shares Sold: 40,000,000 shares of common stock.
- Gross Proceeds: Approximately $1.08 billion.
- Company Proceeds: $0. The Company did not receive any proceeds from the sale as the shares were sold by a selling stockholder.
- Underwriter: Goldman Sachs & Co. LLC.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
The primary material change reported is the completion of the secondary offering by Maple Holdings B.V. ("Maple"), a majority-owned subsidiary of JAB Holdings B.V. ("JAB"). Key changes include:
- Maple sold 40,000,000 shares to the public.
- JAB directly purchased 7,380,000 shares in the offering at the same price paid by the underwriter.
- Following the transaction, Maple and JAB collectively own approximately 62.8% of the Company's outstanding Common Stock.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or an outlook for future performance. It references a press release (Exhibit 99.1) for further details on the closing of the offering but does not explicitly list risks or contingencies within the text of this summary. The transaction was executed under an Underwriting Agreement dated May 20, 2020.
Investor Verification Checklist
- Verify the exact ownership percentage of Maple and JAB post-offering (stated as approx. 62.8%).
- Confirm that the Company received zero proceeds from the $1.08 billion transaction.
- Review the Underwriting Agreement (Exhibit 1.1) for lock-up provisions or future selling rights.
- Check the referenced press release (Exhibit 99.1) for any additional commentary on the strategic rationale for the sale.